Global Alzheimer’s Initiative Now Act

Bill Number

H.R. 3674

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-06-03: Referred to the House Committee on Foreign Affairs.

Last Updated

2026-07-01T08:08:51Z

AI-Generated Summary

Purpose of the Legislation

The Global Alzheimer's Initiative Now Act (H.R. 3674) aims to authorize U.S. participation in the Davos Alzheimer's Collaborative (DAC), a global public-private partnership launched in 2021. The bill seeks to advance international efforts to prevent, diagnose, and treat Alzheimer's disease and dementia, particularly in low- and middle-income countries where cases are rising fastest. It emphasizes U.S. leadership in multilateral health initiatives to address the growing global burden of the disease, which affects nearly 60 million people worldwide and is projected to triple by 2050.

Key Provisions

• Findings Section: Outlines the scale of Alzheimer's globally, including its economic costs (over $1.3 trillion annually), disproportionate impacts on women, minorities, and low/middle-income countries, and demographic trends like aging populations straining health systems. It highlights DAC's role in raising $700 million over six years to innovate in drug development, diagnostics, and care across 12 countries, including the U.S.
• Statement of Policy: Establishes U.S. policy to lead cooperative efforts against Alzheimer's, focusing on diverse populations, international development, and leveraging U.S. investments through burden-sharing in initiatives like DAC.
• Authorization for Participation:
• Authorizes the U.S. to join and contribute to DAC using funds from the Foreign Assistance Act of 1961 (which supports international aid programs).
• The President may designate a qualified federal employee (with expertise in development and public health) from a relevant agency to represent the U.S. on DAC's Advisory Council and potentially its Board of Directors. This designee must coordinate with the USAID Administrator, Secretary of State, and Secretary of Health and Human Services.
• Funding and Matching Requirements: U.S. contributions are limited; they cannot exceed 33% of DAC's total funding from all sources during fiscal years 2026–2030. Funds must be matched by non-U.S. sources to ensure shared responsibility.
• Reporting Requirements: The President must submit a report to Congress within 180 days of enactment and annually thereafter, covering planned U.S. contributions, governance participation, total DAC funding sources, and alignment with U.S. health strategies. Reports go to specified congressional committees (e.g., House and Senate Foreign Affairs/Foreign Relations and Appropriations).

Significant Changes to Existing Law

This bill introduces new authorization to use existing foreign assistance funds (under the Foreign Assistance Act) specifically for DAC, which was not previously enabled. It adds a structured U.S. role in a private-public global health venture, including governance representation and strict matching limits to prevent over-reliance on U.S. funding. No amendments to prior laws are made; instead, it builds on the U.S.'s history of leading multilateral health efforts (e.g., funding for Gavi or the Global Fund).

Potential Impacts

• On Government Agencies: Enhances coordination among the State Department, USAID, and Health and Human Services, potentially integrating DAC into broader U.S. global health programs (e.g., $12 billion in FY 2024 funding). It promotes efficiency through burden-sharing but requires ongoing congressional reporting, increasing oversight.
• On Citizens: Could accelerate research and treatments benefiting U.S. populations, especially the projected 12.7 million Americans with Alzheimer's by 2050, including disproportionately affected minorities and women. Indirectly supports caregivers (70% women) by improving global care models.
• On International Relations: Strengthens U.S. leadership in global health diplomacy, fostering cooperation with 12+ countries and leveraging DAC's work in low/middle-income nations (70% of cases). It encourages private and international funding, reducing U.S. financial burden while advancing shared goals like epidemic preparedness.

Main Stakeholders Affected

• U.S. Government Entities: Departments of State, Health and Human Services, and USAID; congressional committees for oversight.
• Global Health Organizations: DAC and partners (e.g., 19 healthcare systems in 12 countries), including multilateral bodies like the World Bank or Global Fund.
• Citizens and Communities: People with Alzheimer's/dementia worldwide (especially in low/middle-income countries), U.S. minorities, women caregivers, and aging populations facing rising care costs.
• Private Sector: DAC's public-private partners contributing funds and expertise in drug development and healthcare innovation.

Notable Legal, Constitutional, or Political Implications

• Legal: Provides clear statutory authority for U.S. involvement in a non-governmental collaborative, ensuring contributions align with foreign aid laws while imposing fiscal safeguards (e.g., matching caps) to avoid unauthorized spending. The annual reporting promotes transparency and accountability to Congress.
• Constitutional: Aligns with Congress's power to regulate foreign commerce and appropriate funds (Article I), without infringing on executive foreign affairs authority—the bill delegates designee powers to the President but requires coordination and reporting.
• Political: Signals bipartisan support (introduced by Reps. Bera, Fitzpatrick, and Kim) for global health investment amid domestic aging challenges. It could enhance U.S. soft power in health diplomacy but may face scrutiny over foreign aid priorities in budget debates, emphasizing leverage through private matching to appeal to fiscal conservatives. No overt controversies, as it focuses on a non-partisan public health issue.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Bera, Ami [D-CA-6]

Cosponsors (5)

Rep. Fitzpatrick, Brian K. [R-PA-1], Rep. Kim, Young [R-CA-40], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Carson, André [D-IN-7], Rep. Suozzi, Thomas R. [D-NY-3]

Recent Actions

• 2025-06-03: Referred to the House Committee on Foreign Affairs.
• 2025-06-03: Introduced in House
• 2025-06-03: Introduced in House

Bill Versions

• Global Alzheimer’s Initiative Now Act — issued 2025-06-03 — PDF (8 pages)